199 related articles for article (PubMed ID: 25427746)
1. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Xiong Y; Yuan Z; Yang J; Xia C; Li X; Huang S; Zhang H; Liu M
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):117-24. PubMed ID: 25427746
[TBL] [Abstract][Full Text] [Related]
2. The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers.
Wang Z; Xiang Q; Cui Y; Zhao X; Zhou Y
Drug Metab Pharmacokinet; 2013; 28(3):239-43. PubMed ID: 23257391
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
Zhou Q; Ruan ZR; Yuan H; Zeng S
Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
7. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
Choi JH; Lee YJ; Jang SB; Lee JE; Kim KH; Park K
Br J Clin Pharmacol; 2007 Aug; 64(2):185-91. PubMed ID: 17391324
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
10. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
11. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
Xiang Q; Cui YM; Zhao X; Yan L; Zhou Y
Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
[TBL] [Abstract][Full Text] [Related]
12. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects.
Guo X; Chen XP; Cheng ZN; Luo X; Guo R; Chen L; Chen J; Chen B; Peng J; Li YJ
Clin Chem Lab Med; 2009; 47(1):38-43. PubMed ID: 19072027
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort.
Zhao Y; Zhai D; He H; Li T; Chen X; Ji H
Eur J Clin Pharmacol; 2009 Jun; 65(6):579-84. PubMed ID: 19205682
[TBL] [Abstract][Full Text] [Related]
15. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
[TBL] [Abstract][Full Text] [Related]
16. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.
Wu P; Ni X; Wang M; Xu X; Luo G; Jiang Y
Ann Transplant; 2011; 16(1):54-60. PubMed ID: 21436775
[TBL] [Abstract][Full Text] [Related]
19. Conversion from Twice-Daily Prograf
Yau WP; Loh CW; Vathsala A
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):481-492. PubMed ID: 30471066
[TBL] [Abstract][Full Text] [Related]
20. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
